Tackling cancer through artificial intelligence, antimicrobial resistance, neurodegenerative diseases, rare disease diagnosis, clinical trial data, and patient adherence are the topics proposed for IMI’s next Calls for proposals.
We have published the draft texts of the topics that are slated for inclusion in IMI’s next Calls for proposals, IMI2 – Calls 22 and 23, on the Future Topics page of our website. The Calls are both scheduled for launch on 23 June 2020.
IMI2 – Call 22 is a single-stage Call for proposals designed to support research activities that will build on, and add value to, results from certain ongoing IMI2 projects.
IMI2 – Call 23 is a standard, two-stage Call for proposals with the following topics:
- Returning clinical trial data to study participants within a GDPR compliant and approved framework
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
This topic is part of IMI’s Antimicrobial Resistance (AMR) Accelerator programme.
- A platform for accelerating biomarker discovery and validation to support therapeutics development for neurodegenerative diseases
- Optimal treatment for patients with solid tumours in Europe through artificial intelligence
- Shortening the path to rare disease diagnosis by using new born genetic screening and digital technologies
- Behavioural model of factors affecting patient adherence
Currently, the draft topics are currently under consultation with IMI’s States Representatives Group and Scientific Committee. It is therefore likely that the topics may change considerably between now and the Call launch. Nevertheless, we hope that these drafts will allow potential applicants to start working actively on proposals and forming consortia.
Download the draft texts from the IMI Future Topics page
Find out about the IMI Call process, including how topics are generated
Important note: All information regarding future IMI Call topics is indicative and subject to change. Final information about future IMI Calls will be communicated after approval by the IMI Governing Board.